Poor pretransplantation minimal residual disease clearance as an independent prognostic risk factor for survival in myelodysplastic syndrome with excess blasts: A multicenter, retrospective cohort study

Minimal residual disease (MRD) is an important prognostic factor for survival in adults with acute leukemia. The role of pretransplantation MRD status in myelodysplastic syndrome with excess blasts (MDS‐EB) is unknown. This study retrospectively analyzed the relationship between pretransplantation MRD status and long‐term survival.

[1]  P. Fenaux,et al.  International Working Group (IWG) Response Criteria and Association with Overall Survival in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents - a Systematic Review and Meta-Analysis , 2022, Blood.

[2]  H. Votavova,et al.  RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS , 2022, Leukemia.

[3]  Abstracts of Presentations at the Association of Clinical Scientists 143rd Meeting Louisville, KY May 11-14,2022. , 2022, Annals of clinical and laboratory science.

[4]  Elizabeth M. Hollinger,et al.  NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022. , 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

[5]  M. Voso,et al.  Have we reached a molecular era in myelodysplastic syndromes? , 2021, Hematology. American Society of Hematology. Education Program.

[6]  Daniel R. Richardson,et al.  Evidence-Based Minireview: Molecular precision and clinical uncertainty: should molecular profiling be routinely used to guide risk stratification in MDS? , 2021, Hematology. American Society of Hematology. Education Program.

[7]  A. Karsan,et al.  Differentiation therapy for myeloid malignancies: beyond cytotoxicity , 2021, Blood Cancer Journal.

[8]  E. Padron,et al.  It is time to shift the treatment paradigm in myelodysplastic syndromes: A focus on novel developments and current investigational approaches exploring combinatorial therapy in high-risk MDS. , 2021, Best practice & research. Clinical haematology.

[9]  C. Niederwieser,et al.  Current status of pretransplant intensive chemotherapy or hypomethylating agents for myelodysplastic syndrome? , 2021, Best Practice & Research Clinical Haematology.

[10]  K. Pradhan,et al.  ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine , 2021, Blood Cancer Journal.

[11]  Hong-jie Shen,et al.  The Prognostic Value of Early Detection of Minimal Residual Disease as Defined by Flow Cytometry and Gene Mutation Clearance for Myelodysplastic Syndrome Patients After Myeloablative Allogeneic Hematopoietic Stem-Cell Transplantation , 2021, Frontiers in Oncology.

[12]  Wei Zhou,et al.  Pre-transplant therapy for patients with myelodysplastic syndromes: A systematic review and meta-analysis. , 2021, Leukemia research.

[13]  T. Karantanos,et al.  Biology and clinical management of hypoplastic MDS: MDS as a bone marrow failure syndrome. , 2021, Best practice & research. Clinical haematology.

[14]  U. Platzbecker,et al.  Current challenges and unmet medical needs in myelodysplastic syndromes , 2021, Leukemia.

[15]  A. Goldberg,et al.  Relapse after allogeneic stem cell transplantation of acute myeloid leukemia and myelodysplastic syndrome and importance of second cellular therapy. , 2021, Transplantation and cellular therapy.

[16]  Jun Kato,et al.  Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome in adolescent and young adult patients , 2021, Bone Marrow Transplantation.

[17]  C. Hourigan,et al.  Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations , 2021, Leukemia.

[18]  A. Stamatoullas,et al.  Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM) , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  D. Faller,et al.  Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML , 2021, Leukemia.

[20]  Jiang F Zhong,et al.  Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant , 2020, Leukemia.

[21]  G. Garcia-Manero,et al.  Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management , 2020, American journal of hematology.

[22]  A. Logan,et al.  Clinical Significance and Management of MRD in Adults With Acute Lymphoblastic Leukemia. , 2020, Clinical advances in hematology & oncology : H&O.

[23]  M. Walter,et al.  Genetics of Progression from MDS to Secondary Leukemia. , 2020, Blood.

[24]  Lei Gao,et al.  Pegylated liposomal doxorubicin for myeloid neoplasms , 2019, Anti-cancer drugs.

[25]  P. Kong,et al.  Study on the Prognostic Value of Aberrant Antigen in Patients With Acute B Lymphocytic Leukemia. , 2019, Clinical lymphoma, myeloma & leukemia.

[26]  M. Konopleva,et al.  Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts , 2019, American journal of hematology.

[27]  B. Cho,et al.  Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[28]  K. Götze,et al.  Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. , 2018, The Lancet. Oncology.

[29]  J. Lancet,et al.  Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML) , 2017, Leukemia.

[30]  A. Ganser,et al.  Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. , 2017, Blood.

[31]  Christopher A. Miller,et al.  TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. , 2016, The New England journal of medicine.

[32]  Yoo-Jin Kim,et al.  Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts , 2016, Oncotarget.

[33]  J. Bourhis,et al.  Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant R , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[34]  Ya-Zhen Qin,et al.  Minimal residual disease monitoring and preemptive immunotherapy in myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation , 2016, Annals of Hematology.

[35]  T. Gooley,et al.  Relapse after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: Analysis of Late Relapse Using Comparative Karyotype and Chromosome Genome Array Testing. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[36]  I. Weissman,et al.  Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia , 2013, Leukemia.

[37]  C. Steidl,et al.  Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. , 2012, Blood.

[38]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[39]  John P Klein,et al.  Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. , 2002, Blood.

[40]  A. Hagemeijer,et al.  Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. , 2001, Blood.

[41]  D. Weisdorf,et al.  Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.